ClinicalTrials.gg
WithdrawnNCT03473483NIDA-SRECUpdated Dec 9, 2022

Cigarette Harm Reduction With Electronic Cigarette Use

An interventional study of SREC in Nicotine Dependence, Tobacco Toxicity and Nicotine Dependence, Cigarettes, sponsored by University of California, San Francisco. Withdrawn at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Basic science

Why this study was withdrawn
Major study re-design prior to participant enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Tobacco Use Disorder by University of California, San Francisco — 5 open to participants now, 5 under way, none of them phase 3. Tobacco Use Disorder · University of California, San Francisco.

Enrollment
30th of 31
0 · median 108
Started
2022
with 1 other
No phase
21 of 32
3 open now
Registered
16th of 32
by date

Among the 32 studies in Tobacco Use Disorder by University of California, San Francisco, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2022, is one of 21 with no phase, and was the 16th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 32 studies in Tobacco Use Disorder by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tobacco Use Disorder by University of California, San Francisco, or all of them as a file.
02

Study summary

This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.

Read the detailed description

Daily cigarette smokers who are familiar with e-cigarette (EC) use will be instructed to use only NIDA Standardized Research Electronic Cigarettes (SREC) and tobacco cigarettes (TC) while enrolled on the study. Our overall goals are two-fold: (1) to compare nicotine and toxicant exposure and pharmacological effects of SREC used alone vs tobacco cigarettes alone (TC), or dual use; and (2) using SREC alone, TC alone, or ad libitum SREC use combined with 50% reduction in usual TC use as a model for dual use, to examine the extent to which nicotine and toxicant exposure and biomarkers of potential harm compare among the 3 groups. The former would inform the effects of total switching, the latter would inform the potential harm reducing effects of smoking fewer TC while using EC.

03

Conditions studied

  • Nicotine Dependence
  • Tobacco Toxicity
  • Nicotine Dependence, Cigarettes
  • Cardiovascular Risk Factor
  • Nicotine Withdrawal

Keywords

  • nicotine
  • tobacco
  • research electronic cigarette
  • e-cigarette
  • SREC
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of medical history and limited physical examination as described below:
    • Heart rate \< 105 beats per minute (BPM)
    • Systolic Blood Pressure \< 160 and > 90
    • Diastolic Blood Pressure \< 100 and > 50
    • ≤ 38.0
    • Expired Carbon Dioxide (CO) >=5ppm
  • Current regular "dual" user of both electronic cigarette (EC) and tobacco cigarette (TC)
  • EC device use at least 10 or more days in the past 30 days
  • Daily use of conventional TC (at least 10 cigarettes per day (CPD), as confirmed by saliva cotinine >50 ng/ml and/or NicAlert=6)
  • Age: >= 21 years old to \<= 70 years old
  • Willingness to use a non-menthol e-cigarette only (until menthol flavored SREC becomes available)
  • Willingness to abstain from marijuana for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Unstable medical conditions (such as unstable heart disease, seizures, cancer, uncontrolled thyroid disease, diabetes, or C or renal or liver impairment, glaucoma, history of stroke, an ulcer in the past year, or active use of an inhaler for Asthma or (COPD).
  • Psychiatric conditions (such as current or past schizophrenia and/or current or past bipolar disorder, major personality disorder, or major depression current or within the past year. Participants with current or past minor to moderate depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion. Psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval.
  • Psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin and norepinephrine reuptake inhibitors (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable and able to participate.
  • Pregnancy or breastfeeding (by history and pregnancy test); women of must be using an acceptable method of
  • Concurrent regular use of marijuana [occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study]
  • Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos, blunts/spliffs [no more than 15 times in combination in the past month and must agree to abstain from their use during the period of the study.]
  • Concurrent use of nicotine-containing medications
  • Alcohol or illicit drug dependence within the past 12 months (with the exception of those who have recently completed an alcohol/drug treatment program). Positive toxicology test at the screening visit (THC ok). Must not be on opioid replacement therapy.
  • Medications: Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs). Use of medications for cardiovascular conditions including hypertension (Example: beta- and alpha-blocking drugs). Use of stimulants (Example: Adderall)
  • Other/Misc Health Conditions: Oral thrush; fainting within the last 30 days; untreated thyroid disease; other "life threatening illnesses" as per study physician's discretion.
  • Concurrent participation in another clinical trial
  • Inability to read and write in English
  • Planning to quit smoking or vaping within the next 60 days
  • A known propylene glycol/vegetable glycerin allergy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    SREC only or cigarette only use

    Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.

    Other: SREC

  • Experimental
    Alternate product from Arm 1

    Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.

    Other: SREC

  • Experimental
    Standardized Dual Use

    Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.

    Other: SREC

Interventions

  • OtherSREC

    The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices. Tank: * Sealed and disposable * Minimum 350 puffs per tank * Volume of e-liquid per tank \~ 3ml E-Liquid Characteristics: * Tobacco flavored * Nicotine concentration: 15 mg/ml * Propylene Glycol:\~ 50% (wt / wt) * Glycerin: \~ 50% (wt / wt) * Cotinine: \<1 μg/g * Nornicotine: 5 μg/g * Myosmine : 3 μg/g * Anabasine: \<1 μg/g * Anatabine: \<1 μg/g * Beta:nicotyrine: \<1 μg/g * Diacetyl: \<2 μg/g * 2,3:Pentanedione: \<1 μg/g * Arsenic: \<0.1 μg/g * Cadmium: \<0.1 μg/g * Chromium: \<0.1 μg/g * Lead: \<0.1 μg/g * Nickel: \<0.1 μg/g * Mercury: \<0.05 μg/g

    Also known as: Standardized Research E-Cigarette

06

What researchers measure

Primary outcomes

  1. Peak Nicotine Concentration

    Compare peak nicotine concentration between SREC vs. Tobacco Cigarette (TC) use

    Time frame: Up to 2 years

  2. Time of Peak Nicotine Concentration

    Compare time of peak nicotine concentration between SREC vs. Tobacco Cigarette (TC) use

    Time frame: Up to 2 years

  3. Mean overall systemic nicotine exposure

    Descriptive statistics will be used to examine systemic nicotine exposure from daily use of SREC and compare daily nicotine intake to TC use

    Time frame: Baseline through study completion, approximately 2 years

  4. Change in Mean score on the Modified Cigarette Evaluation Questionnaire (mCEQ)

    The mCEQ use three multi-item domains (subscales) and two single items: "Smoking Satisfaction", "Psychological Reward", "Aversion", "Enjoyment of Respiratory Tract Sensations" and "Craving Reduction". Scores for each subscale are calculated as the average of its individual item responses of The items are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely). Higher scores indicate greater intensity of each smoking effect with, for example, greater satisfaction or psychological reward after smoking. Scores will be compared between SREC, TC, and dual use

    Time frame: Baseline through study completion, approximately 2 years

  5. Patterns of puffing

    Compare the pattern of puffing between SREC and TC use by coding the recorded ad libitum use of SREC vs TC.

    Time frame: Baseline through study completion, approximately 2 years

  6. Change in Mean score on the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R)

    The MTWS-R features two separate measures for examining the severity of nicotine withdrawal symptoms in a participant: a self-report scale and an observer scale. The observer scale asks the scale-taker to rate the severity of four symptoms in someone the they know who is experiencing nicotine withdrawal: "angry/irritable/frustrated," "anxious/tense," "depressed," and "restless/impatient." The self-report version asks for rankings of the severity of those same four symptoms, plus eleven others that cannot be observed by outsiders (including such things as "desire or craving to smoke," "insomnia, sleep problems, awakening at night," or "dizziness). Both scales use a Likert-type scale for the severity ratings, ranging from 0 ("not at all") to 4 ("severe"). These scores are tallied to calculate an a total withdrawal discomfort score and will be compared between SREC, TC, and dual use.

    Time frame: Baseline through study completion, approximately 2 years

  7. Change in Mean score on the Questionnaire on Smoking Urges (QSU-Brief)

    The QSU-Brief consists of 10 statements about the respondent's feelings and thoughts about his or her desire to smoke cigarettes as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree) and total scores are calculated by summing the item scores to compare craving between SREC, TC, and dual use.

    Time frame: Baseline through study completion, approximately 2 years

  8. Change in Mean score on the Positive and Negative Affect Scale (PANAS)

    The Positive and Negative Affect Schedule (PANAS) is a brief scale is comprised of 20 items, with 10 items measuring positive affect (e.g., excited, inspired) and 10 items measuring negative affect (e.g., upset, afraid). Each item is rated on a five-point Likert Scale, ranging from 1 = Very Slightly or Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame and the final score is derived out of the sum of the ten items on both the positive and negative side. Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The scores will be comparted between SREC, TC, and dual use.

    Time frame: Baseline through study completion, approximately 2 years

Secondary outcomes

  1. Changes in mean circadian heart rate

    Compare changes in mean circadian heart rate between SREC-only and TC-only use

    Time frame: Baseline through study completion, approximately 2 years

  2. Changes in mean blood pressure

    Compare changes in blood pressure between SREC-only and TC-only use

    Time frame: Baseline through study completion, approximately 2 years

  3. Changes in mean urinary catecholamine

    Compare mean urinary catecholamine excretion between SREC-only and TC-only use

    Time frame: Baseline through study completion, approximately 2 years

  4. Mean Level of exposure to Tobacco smoke toxicant

    Compare levels of exposure of tobacco smoke toxicant between dual SREC-TC use and TC-only use

    Time frame: Baseline through study completion, approximately 2 years

  5. Sensitivity of anabasine or nicotelline to nicotine metabolites

    Sensitivity is defined as the ratio of anabasine or nicotelline to nicotine metabolites (cotinine or total nicotine equivalents) in urine from SREC-only and TC-only use.

    Time frame: Baseline through study completion, approximately 2 years

  6. Specificity of anabasine or nicotelline to nicotine metabolites

    Specificity of anabasine or nicotelline will be compared to nicotine metabolites (cotinine or total nicotine equivalents) in urine from SREC-only and TC-only use.

    Time frame: Baseline through study completion, approximately 2 years

07

Study locations

1 site
  • UCSF Tobacco Research Center
    San Francisco, California 94110, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Mar 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Mar 22, 2018
StartActual
Aug 1, 2022
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03473483
Responsible party
Sponsor
First posted
Mar 22, 2018
Start date
Aug 1, 2022
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Dec 9, 2022

Study contacts

Neal L. Benowitz, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion